Effectiveness of axicabtagene ciloleucel versus conventional treatments as first-line therapy for high-risk large B-cell lymphoma: an external comparator study
In the present study, we leveraged real-world data as a source for external comparator to present clinically meaningful evidence on the comparative effectiveness of axi-cel for treatment of high-risk LBCL.
Authors
- Yeeun Choi (ORCID: https://orcid.org/0000-0001-7486-9102)
- Sungho Bea (ORCID: https://orcid.org/0000-0003-2622-6553)
- Ju Hwan Kim (ORCID: https://orcid.org/0000-0001-7253-6515)
- Sang Eun Yoon (ORCID: https://orcid.org/0000-0002-0379-5297)
- Won Seog Kim (ORCID: https://orcid.org/0000-0002-5400-0466)
- Seok Jin Kim
- Ju‐Young Shin (ORCID: https://orcid.org/0000-0002-2791-1037)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Samsung Medical Center (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1186/s12885-025-15134-4
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- Ministry of Food and Drug Safety
- Korea Health Industry Development Institute
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea